CRESEMBA Pfizer Australia Pty Ltd
Product name
CRESEMBA
Sponsor
Accepted date
Jul-2024
Active ingredients
isavuconazonium sulfate
Proposed indication
CRESEMBA is indicated in adults and paediatric patients from 1 year of age for the treatment of
• invasive aspergillosis
• mucormycosis in patients for whom amphotericin B is inappropriate.
• invasive aspergillosis
• mucormycosis in patients for whom amphotericin B is inappropriate.
Application type
C (new indication)
Publication date
Jul-2024